Amgen Inc.
 (AMGN)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • May 6, 2013, 7:33 AM

    Transgenomic (TBIO.OB) enters into a collaborative agreement with Amgen (AMGN) for the further development of a CE-IVD test for the detection of RAS mutations in patients with metastatic colorectal cancer. (PR)

    | May 6, 2013, 7:33 AM
  • May 3, 2013, 5:43 PM

    An FDA panel has voted 17-1 that Amgen's (AMGN) blood-boosting drugs would benefit radiation survivors in the event of a nuclear attack. The drugs, known as Leukocyte growth factor drugs, are normally given to cancer patients to combat the effects of chemotherapy. The panel observed monkeys exposed to radiation, and those given AMGN's Neupogen showed a greater likelihood of survival, and the FDA says it's likely to provide the same benefit to people as well.

    | May 3, 2013, 5:43 PM
  • May 3, 2013, 4:18 PM
    By a 17-1 margin, the FDA votes Amgen's (AMGN +0.8%) Neulasta and Neupogen drugs could improve survival rates for people exposed to radiation following a nuclear attack. Bloomberg recently observed Neulasta and Neupogen , which are used to prevent infection during chemotherapy, collectively produced ~$5.4B in 2012 sales for Amgen.
    | May 3, 2013, 4:18 PM
  • May 1, 2013, 7:51 AM

    Goldman adds Amgen (AMGN) to its coveted Conviction Buy list saying investors have already factored in Q4 and H2 2015 patent expirations for some of the company's "key biologic franchises." Furthermore, AMGN's pipeline and "own biosimilars will allow it to replace the potential revenue that could be lost to competition." Shares +2% premarket.

    | May 1, 2013, 7:51 AM
  • Apr. 24, 2013, 12:56 PM

    Amgen (AMGN -5.8%) slides after posting a mixed Q1 report late yesterday, beating on its EPS but coming up short on earnings. Net profit rose 21% Y/Y, due largely to a significantly lower tax rate, but the better number fails to mask disappointing sales, especially of its key arthritis drug Enbrel. The drug saw sales rise 11%, but fell short of analysts expectations. Piper Jafray cut the shares to Neutral on the report, saying the stock has limited upside until late stage clinical catalysts provide visibility into future growth.

    | Apr. 24, 2013, 12:56 PM
  • Apr. 23, 2013, 4:04 PM
    Amgen (AMGN): Q1 EPS of $1.96 beats by $0.12. Revenue of $4.238B (+5% Y/Y) misses by $0.14B. Shares +0.3% AH. (PR)
    | Apr. 23, 2013, 4:04 PM | 2 Comments
  • Apr. 23, 2013, 12:10 AM

    Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI

    | Apr. 23, 2013, 12:10 AM
  • Apr. 22, 2013, 5:35 PM

    Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI

    | Apr. 22, 2013, 5:35 PM
  • Apr. 16, 2013, 5:48 PM

    Amgen (AMGN) has agreed to to pay $24.9M to settle allegations that it violated the False Claims Act by paying kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine. The DoJ claims the payments were made to Omnicare (OCR), PharMerica (PMC) and Kindred Healthcare (KND) in return for implementing "therapeutic interchange" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to AMGN's Aranesp.

    | Apr. 16, 2013, 5:48 PM
  • Mar. 28, 2013, 4:24 PM
    Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 
    | Mar. 28, 2013, 4:24 PM | 1 Comment
  • Mar. 27, 2013, 3:08 PM
    Amgen (AMGN +1%) and Johnson & Johnson (JNJ +0.5%) also hit new 52-week highs today on the back of developments stemming from Kinmed and PFE's non-exclusive partnership.
    | Mar. 27, 2013, 3:08 PM
  • Mar. 20, 2013, 8:31 AM

    Amgen's (AMGN) TVEC meets its primary endpoint in a Phase III trial by significantly reducing tumors in 16% of melanoma patients for at least six months vs only 2% in a control group. However, Amgen says its too early to say if TVEC helps patients live longer and if it will file for regulatory approval based on the results of the study. TVEC is a herpes simplex virus that Amgen has modified to kill cancer cells. (PR)

    | Mar. 20, 2013, 8:31 AM
  • Mar. 6, 2013, 5:27 PM
    Amgen, Inc. (AMGN) declares $0.47/share quarterly dividend, in line with previous. Forward yield 2.02%. For shareholders of record May 16. Payable June 07. Ex-div date May 14. (PR)
    | Mar. 6, 2013, 5:27 PM
  • Mar. 3, 2013, 4:02 AM

    Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an autoimmune skin disease, by 75% in a third of patients in a Phase III trial. However, that's below the 41% rate in a Phase II study, raising doubts about whether Apremilast will meet Celgene's hopes and become a new blockbuster drug. Apremilast would compete with rival medicines from AbbVie (ABBV) and Amgen (AMGN). (PR)

    | Mar. 3, 2013, 4:02 AM
  • Feb. 26, 2013, 1:04 PM
    Amgen (AMGN +0.1%) says the FDA has halted all pediatric clinical trials of Sensipar after a reported death of a 14-year-old patient taking part in a study of the drug used to lower calcium levels in the blood. AMGN however, says that there's no conclusion on Sensipar's role in the death as outlined by the FDA, and it was still working with the agency on the drug's development.
    | Feb. 26, 2013, 1:04 PM
  • Feb. 25, 2013, 7:28 AM

    Affymax (AFFY) prints at $3.41 premarket, -78.8%, following yesterday's report of the Omontys recall. AFFY has no other late-stage drugs in its pipeline. Piper expects shares to trade to cash value (~$2) "as investors take into account the lack of visibility." In play: AMGN, whose Epogen dominates the antianemia market (+2.4%), NKTR (which earns royalties on Omontys sales), and FMS, which pulled a trial two weeks ago (-1.3%).

    | Feb. 25, 2013, 7:28 AM
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States